|
PHAX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.39153141734505E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.90020230053756E-11 |
| Normal-vs-Stage2 |
2.35349999999634E-05 |
| Normal-vs-Stage3 |
5.0457005240645E-10 |
| Normal-vs-Stage4 |
2.24329999021222E-10 |
| Stage1-vs-Stage2 |
5.102800E-01 |
| Stage1-vs-Stage3 |
3.799800E-01 |
| Stage1-vs-Stage4 |
1.133050E-01 |
| Stage2-vs-Stage3 |
2.563000E-01 |
| Stage2-vs-Stage4 |
7.809600E-02 |
| Stage3-vs-Stage4 |
4.196800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.14794848574229E-12 |
| Normal-vs-AfricanAmerican |
2.517000E-03 |
| Normal-vs-Asian |
3.00539999997795E-07 |
| Caucasian-vs-AfricanAmerican |
1.420580E-01 |
| Caucasian-vs-Asian |
8.615400E-01 |
| AfricanAmerican-vs-Asian |
2.307600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.91797705390218E-12 |
| Normal-vs-Female |
3.07099901064589E-11 |
| Male-vs-Female |
1.717990E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.2469000276738E-09 |
| Normal-vs-Age(41-60Yrs) |
3.7584046985728E-11 |
| Normal-vs-Age(61-80Yrs) |
4.33060032278831E-10 |
| Normal-vs-Age(81-100Yrs) |
5.379200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.192200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.523600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.087000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.327000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.272800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.619400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.140100E-02 |
| Classical-VS-Follicular |
1.652350E-02 |
| Classical-VS-Other |
8.316400E-02 |
| Classical-VS-Normal |
1.21099996697183E-09 |
| Tall-VS-Follicular |
7.895200E-01 |
| Tall-VS-Other |
4.107800E-01 |
| Tall-VS-Normal |
9.3201000028742E-08 |
| Follicular-VS-Other |
3.829400E-01 |
| Follicular-VS-Normal |
2.93139956752952E-10 |
| Other-VS-Normal |
3.550300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02829966763807E-10 |
| Normal-vs-N1 |
1.07120001757721E-09 |
| N0-vs-N1 |
1.172150E-01 |
|
|
